Description
Determination of EML4-ALK, ROS1 translocations and MET gene exon 14 loss is recommended for all patients with locally advanced and metastatic non-small cell lung cancer to determine eligibility for targeted therapy.
Period of execution
Within 12 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Tissue sample
- Tissue sample in paraffin block